AXGN

SEC source: 0000805928-26-000101 · wk-form4_1788552483.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,650

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $48.01 to $51.46 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-26-000098 · wk-form4_1786565567.xml · derivative · entry 3

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,353 shares

Expires 2027-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 14, 2018.

SEC source: 0000805928-26-000098 · wk-form4_1786565567.xml · nonDerivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,976

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2026.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.82 to $49.02 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-26-000098 · wk-form4_1786565567.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-26-000099 · wk-form4_1786565598.xml · derivative · entry 3

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 67,500 shares

Expires 2033-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the stock option grant will be fully vested on March 1, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate stock options vest on March 1, 2025 (24 months from the grant date) and an additional 12.5% of the aggregate stock options vest each 6 months thereafter.

SEC source: 0000805928-26-000099 · wk-form4_1786565598.xml · nonDerivative · entry 2

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,135

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-26-000099 · wk-form4_1786565598.xml · nonDerivative · entry 1

Began Marc A · CIK 0001821352 · EVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,635

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-26-000096 · wk-form4_1786479331.xml · nonDerivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2026.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.43 to $46.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001682069-26-000002 · wk-form4_1782507192.xml · derivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0001410781-26-000008 · wk-form4_1782507185.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000089 · wk-form4_1782507176.xml · derivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000088 · wk-form4_1782507169.xml · derivative · entry 1

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,579

Underlying: Common Stock · 5,579 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $235,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $235,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000087 · wk-form4_1782507161.xml · derivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.underlying: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000086 · wk-form4_1782507152.xml · derivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0001400568-26-000015 · wk-form4_1782507140.xml · derivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000080 · wk-form4_1782247037.xml · derivative · entry 2

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000080 · wk-form4_1782247037.xml · nonDerivative · entry 1

Levine Alan M · CIK 0001766833 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,893

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0000805928-26-000079 · wk-form4_1782247020.xml · derivative · entry 2

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000079 · wk-form4_1782247020.xml · nonDerivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0001400568-26-000013 · wk-form4_1782246998.xml · derivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0001400568-26-000013 · wk-form4_1782246998.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,976

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0000805928-26-000078 · wk-form4_1782246978.xml · derivative · entry 2

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,867 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $200,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000078 · wk-form4_1782246978.xml · nonDerivative · entry 1

THOMAS PAUL · CIK 0001166776 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,395

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0000805928-26-000077 · wk-form4_1782246960.xml · derivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000077 · wk-form4_1782246960.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0001410781-26-000006 · wk-form4_1782246942.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0001410781-26-000006 · wk-form4_1782246942.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0000805928-26-000076 · wk-form4_1782246910.xml · derivative · entry 2

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000076 · wk-form4_1782246910.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0001400568-26-000009 · wk-form4_1778616387.xml · derivative · entry 3

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,353

Underlying: Common Stock · 1,647 shares

Expires 2027-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the board of director's stock option were fully vested on May 31, 2018.

SEC source: 0001400568-26-000009 · wk-form4_1778616387.xml · nonDerivative · entry 2

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,826

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.50 to $42.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001400568-26-000009 · wk-form4_1778616387.xml · nonDerivative · entry 1

Wendell Amy McBride · CIK 0001400568 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001410781-26-000002 · wk-form4_1778270876.xml · derivative · entry 3

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,050 shares

Expires 2034-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the board of director stock option were fully vested on June 6, 2025.

SEC source: 0001410781-26-000002 · wk-form4_1778270876.xml · nonDerivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.25 to $43.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001410781-26-000002 · wk-form4_1778270876.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-26-000069 · wk-form4_1778270855.xml · derivative · entry 3

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,307

Underlying: Common Stock · 16,344 shares

Expires 2033-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 20, 2024.

SEC source: 0000805928-26-000069 · wk-form4_1778270855.xml · nonDerivative · entry 2

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.04 to $44.26 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-26-000069 · wk-form4_1778270855.xml · nonDerivative · entry 1

Weiler Kathy Johnson · CIK 0001979466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,344

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-26-000068 · wk-form4_1778270821.xml · nonDerivative · entry 1

Kemp Jens · CIK 0002007485 · Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,451

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.44 to $43.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · derivative · entry 6

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,963 shares

Expires 2033-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

SEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · derivative · entry 5

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires 2032-03-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026.

SEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 4

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,146

SEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 3

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 2

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,756

SEC source: 0000805928-26-000067 · wk-form4_1778270803.xml · nonDerivative · entry 1

Hartley Lindsey Marie · CIK 0002068693 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-26-000066 · wk-form4_1778270784.xml · nonDerivative · entry 1

Quackenbush Doris · CIK 0002133244 · Sales VP

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,416

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $44.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · derivative · entry 6

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,575

Underlying: Common Stock · 11,575 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.

F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.

SEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · derivative · entry 5

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,363

Underlying: Common Stock · 6,363 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates.

F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates.

SEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 4

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 262,781

F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.

SEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 3

DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 268,002

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.